$913 Million is the total value of Rhenman & Partners Asset Management AB's 94 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SYMC | Exit | Symantec Corp | $0 | – | -8,761 | -100.0% | -0.03% | – |
| MSFT | Exit | Microsoft Corp | $0 | – | -1,532 | -100.0% | -0.03% | – |
| SNSS | Exit | Sunesis Pharmaceuticals Inc Reg | $0 | – | -377,244 | -100.0% | -0.03% | – |
| ACHN | Exit | Achillion Pharmaceuticals Inc | $0 | – | -277,800 | -100.0% | -0.12% | – |
| ARQL | Exit | ArQule Inc Reg | $0 | – | -200,000 | -100.0% | -0.18% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Inc Reg | $0 | – | -30,000 | -100.0% | -0.32% | – |
| HMSY | Exit | HMS Holdings Corp Reg | $0 | – | -98,300 | -100.0% | -0.42% | – |
| DPLO | Exit | Diplomat Pharmacy Inc Reg | $0 | – | -1,060,000 | -100.0% | -0.65% | – |
| EXEL | Exit | Exelixis Inc | $0 | – | -320,000 | -100.0% | -0.71% | – |
| RARX | Exit | Ra Pharmaceuticals Inc Reg | $0 | – | -244,000 | -100.0% | -0.72% | – |
| CHRS | Exit | Coherus BioSciences Inc | $0 | – | -290,000 | -100.0% | -0.74% | – |
| Exit | Incyte Corp Ltd | $0 | – | -80,000 | -100.0% | -0.74% | – | |
| MDCO | Exit | Medicines Co | $0 | – | -153,000 | -100.0% | -0.96% | – |
| ABC | Exit | AmerisourceBergen Corp | $0 | – | -99,000 | -100.0% | -1.02% | – |
| TMO | Exit | Thermo Fisher Scientific Inc | $0 | – | -38,000 | -100.0% | -1.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-01-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.